PLGA Carriers for inhalation: Where do We stand, Where are We headed?
- 8 October 2015
- journal article
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 6 (10) , 1139-1144
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategiesAdvanced Drug Delivery Reviews, 2014
- Technological and practical challenges of dry powder inhalers and formulationsAdvanced Drug Delivery Reviews, 2014
- Emerging inhalation aerosol devices and strategies: Where are we headed?Advanced Drug Delivery Reviews, 2014
- Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promisesJournal of Pharmacy and Pharmacology, 2012
- PLGA-based nanoparticles: An overview of biomedical applicationsJournal of Controlled Release, 2012
- A strategy to deliver genes to cystic fibrosis lungs: A battle with environmentJournal of Controlled Release, 2011
- Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilatorInternational Journal of Pharmaceutics, 2011
- The Particle has Landed—Characterizing the Fate of Inhaled PharmaceuticalsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivativesJournal of Controlled Release, 2008
- Cyclodextrins in the production of large porous particles: Development of dry powders for the sustained release of insulin to the lungsEuropean Journal of Pharmaceutical Sciences, 2006